DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for extragonadal germ cell cancer — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleExtragonadal germ cell cancer maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for extragonadal germ cell cancer is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphatase and tensin homolog (PTEN) — PTEN is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet +drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1D5R · 2.1 Å · ligand L(+)-TARTARIC ACID (TLA). Experimental structure, not a prediction.
What the evidence adds up to
Thirty-two patients with primary extragonadal germ-cell tumours were treated between 1967 and 1981 at Vanderbilt and Indiana University Hospitals. Thirty-one had far-advanced disease. All received intensive cisplatin-containing combination chemotherapy; residual tumours were surgically removed when feasible. Of 31 evaluable patients, 21 achieved a complete remission and 10 had a partial response. Eighteen patients remained continuously disease-free after a median follow-up of 30 months. Eighty-nine percent of complete responders stayed free of disease, with no relapses after 12 months. Partial responders had a median survival of 9 months and no long-term survivors. The authors concluded that extragonadal germ-cell tumours are as curable as testicular germ-cell tumours with this approach.
A 2012 case report described a 37-year-old man with a primary malignant mixed non-seminomatous germ-cell tumour (teratocarcinoma) in the soft tissue of the right arm, a location not previously reported. He was treated with cisplatin-based chemotherapy and surgery. After 18 months of follow-up, no locoregional recurrence or distant metastases were detected. The authors stated that combination chemotherapy and surgery is the most appropriate treatment strategy for extragonadal germ-cell tumours.
A 2018 case report described a 31-year-old man with a yolk-sac retroperitoneal germ-cell tumour who had normal serum alpha-fetoprotein and lactate dehydrogenase levels, which the authors said had not been previously described. A testicular primary was excluded. The authors noted that extragonadal germ-cell tumours are rare but can be fatal if undiagnosed, and that a high level of suspicion is required for diagnosis and close follow-up.
What is still missing are prospective trials that stratify patients by primary site (retroperitoneal, mediastinal, or other rare locations) and by histologic subtype, given that the 1982 series grouped all extragonadal primaries together and the later reports are single cases. No randomised comparison of different cisplatin-based regimens exists for this specific population. Funding for multi-centre registries or trials that could clarify whether outcomes truly match testicular germ-cell tumours in the modern era, and whether the absence of standard serum markers in some patients delays diagnosis, remains absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Annals of Internal Medicine · 1982 · 162 citations
Advanced Extragonadal Germ-Cell Tumors
AbstractThirty-two patients with primary extragonadal germ-cell tumors were treated at Vanderbilt and Indiana University Hospitals during the period from 1967 to 1981. Thirty-one patients had far-advanced disease when treatment was begun. All patients received intensive cisplatin-containing combination chemotherapy regimens. Tumors remaining after chemotherapy were surgically removed when feasible. Of the 31 evaluable patients, 18 have been continuously disease-free after therapy, 21 patients had a complete remission; the remaining 10 had partial response. Eighty-nine percent of patients with complete remission remain free of disease after median follow-up of 30 months. No relapses occurred after 12 months of complete remission. Patients with partial response had a median survival of 9 months with no long-term survivors. Response rates and survival are similar to patients with advanced-stage testicular germ-cell tumors. Extragonadal germ-cell tumors are as curable as testicular germ-cell tumors when treated with intensive cisplatin-containing combination chemotherapy regimens, and surgical resection when necessary.
World Journal of Surgical Oncology · 2012 · 18 citations · open access
Extragonadal mixed germ cell tumor of the right arm: description of the first case in the literature
AbstractBACKGROUND: Extragonadal localization of germ cell tumors (GCTs) is rare; to the best of our knowledge, a location in the soft tissue of the arm has never been previously reported in the literature. CASE PRESENTATION: We report the case of a 37-year-old man who presented with a primary malignant mixed non-seminomatous GCT (teratocarcinoma variety) in the right arm, treated by a combination of cisplatin-based chemotherapy and surgery. After 18 months of close follow-up, no locoregional recurrence or distant metastases have been detected. CONCLUSIONS: A combination of chemotherapy and surgery is the most appropriate treatment strategy for extragonadal GCTs, to ensure both local and systemic control.
AbstractExtragonadal germ cell tumors are well recognized in men but have rarely been reported in women. Reports have primarily focused on the pediatric population and have suggested a poor prognosis for extragonadal yolk sac tumors. A 23-year-old woman with a yolk sac tumor arising in the rectum is described. A review of the English-language literature (MEDLINE 1966-1998) regarding extragonadal germ cell tumors in females is provided. Treatment with four courses of cisplatin, etoposide, and bleomycin was followed by surgical resection of the involved area. No residual tumor was identified. She remains disease free 3.5 years later. Previous reports are limited by the small number of patients, focus on the pediatric population, and treatment before the availability of cisplatin. Extragonadal germ cell tumors in women are extremely rare but can be successfully treated with aggressive chemotherapy and surgery similar to testis cancer.
European Journal of Case Reports in Internal Medicine · 2018 · 2 citations · open access
An Unusual Case of Primary Retroperitoneal Germ Cell Tumour in a Young Man
AbstractSome 2-5% of germ cell tumours are of extragonadal origin, with a retroperitoneal location being very rare. The majority of retroperitoneal germ cell tumours have metastasized from a testicular tumour. These tumours are diagnosed incidentally or symptomatically and nearly all present with high alpha-fetoprotein and lactate dehydrogenase levels. We describe the unusual case of a 31-year-old man with a yolk-sac, retroperitoneal germ cell tumour, with normal serum alpha-fetoprotein and lactate dehydrogenase levels, which has not previously been described. A testicular tumour was excluded by physical examination and additional tests. Our diagnosis was based on a high level of suspicion and histopathological results. As far as we know, this is the first case described with these characteristics. LEARNING POINTS: Extragonadal germ cell tumours are rare but can have fatal consequences if undiagnosed.The usual laboratory markers of the disease were absent in our patient.A high level of suspicion is required for diagnosis and close follow-up is required.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
